Articles

Results from a study of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to see if treatment with ibrutinib plus venetoclax could be stopped for those who have a good response. Read More ›

Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma. Read More ›

Extended follow-up of the E1912 trial showed a significant advantage for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib + rituximab compared with those treated with fludarabine, cyclophosphamide, and rituximab (FCR). Read More ›

Zanubrutinib is an investigational, next-generation Bruton tyrosine kinase inhibitor. It has been tested in previously untreated patients with del(17p) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who are enrolled in the SEQUOIA trial. Read More ›

CAR T-cell therapy – a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells – could soon be used to fight multiple myeloma. CAR T-cell therapy has shown huge promise in other types of cancer but would be a new treatment for patients with this type of cancer. Read More ›

An updated analysis of combined or pooled data from studies of ibrutinib. For the first time, a comparison of outcomes with ibrutinib versus patients’ prior treatment regimens for mantle-cell lymphoma is shared. Read More ›

Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor that has been shown to be potent and selective. Preliminary data suggest durable clinical responses in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Read More ›

Exciting new research shows that adding daratumumab to a common multiple myeloma treatment slowed down cancer progression in patients who had relapsed or did not respond to other treatments. Read More ›

Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

The ongoing phase 1/2 HOVON 124/Ecwm-R2 trial showed the combination of ixazomib citrate, rituximab, and dexamethasone to be feasible, with promising efficacy and manageable toxicity in patients with relapsed or progressive Waldenström macroglobulinemia. Read More ›